|
| |
CerusAt Cerus Corporation we have developed a platform technology (Helinx®) that prevents nucleic acid (DNA and RNA) replication. The Company's initial application of this technology is the development of the INTERCEPT Blood Systems to inactivate viruses, bacteria and other pathogens in the blood components used for transfusion - platelets, plasma and red blood cells.
| Contact Details: |
| 2411 Stanwell Drive |
| Concord |
| CA |
| 94520 |
| United States of America |
| Tel: | (925) 288-6000 |
| Fax: | (925) 288-6001 |
| Email: | customer_services@cerus.com |
| WWW: | www.ceruscorp.com/
|
|
Loading...
|
Recent Publications by Cerus: |  |
INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis.
Background An effective pathogen inactivation (PI) technology for plasma... | 2nd September, 2009
| Cerus B.V., Amersfoort, the Netherlands.
| Vox Sang. 2009 Aug 30.
DOI Direct Link |
Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
BACKGROUND: It is estimated that approximately 300,000 neonates undergo... | 3rd June, 2009
| Cerus Corporation, Stanwell Drive, Concord, California 94520, USA
| Transfusion. 2009 May;49(5):985-94. Epub 2009 Jan 21.
DOI Direct Link |
Palladium-mediated C5 substitution of pyrimidine nucleosides.
One of the most efficient ways to link a reporter group to... | 15th May, 2008
| Cerus Corp., Concord, California, USA.
| Curr Protoc Nucleic Acid Chem. 2001 May;Chapter 1:Unit 1.1.
DOI Direct Link |
Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.
NK cells can identify and eliminate emerging tumors due to altered... | 6th February, 2008
| Cerus Corporation,
| J Immunol. 2007 Dec 1;179(11):7376-84.
|
Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
BACKGROUND: The human erythrovirus B19 (B19) is a small (18- to 26-nm)... | 7th August, 2007
| Cerus Corporation, Concord, California 94520, USA.
| Transfusion. 2007 Jun;47(6):1062-70.
DOI Direct Link |
→View more Cerus research publications. |
Press Releases on Cerus:
|
 |
| New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Hepatitis C Virus And Therapeutics Market
http://www.reportlinker.com/p0119497/World
|
| Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes |
2nd April, 2009 |
Jazz Pharmaceuticals, Inc. |
PALO ALTO, Calif., April 2 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that Samuel R. Saks, its Chief Executive Officer and a member of its Board of Directors,
|
| Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO |
8th September, 2008 |
Zosano Pharma, Inc. |
FREMONT, Calif., Sept. 8 /PRNewswire/ -- Zosano Pharma, Inc., a privately
held pharmaceutical company developing a novel transdermal delivery
technology, today announced that Gail Schulze has
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 398 times since April 2007, the link to the organisation's website has been followed 54 times Recent Search Terms used to find this page: CERUS BRITISH | . Search for more companies in Concord Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cerus |
